VALFIX Medical

VALFIX Medical is developing a trans-catheter solution for patients suffering from valvular heart disease and heart failure.

VALFIX Medical, a leading innovator in Transcatheter mitral valve repair is proud to announce the approval of its fifth consecutive grant from the Israel Innovation Authority (IIA).

VALFIX Medical Inc. is proud to announce the appointment of Surindra N. Mitruka, MD, MBA, to its board of directors, effective immediately. Dr.

VALFIX Medical Inc. announces today that it has secured its fourth grant from the Israel Innovation Authority.

VALFIX Medical Inc. announced today the appointment of former Abbott Venture Divisional Vice President (DVP), Mr. Evan Norton as the company's independent board member making him the company's fifth board of directors' member.

VALFIX Medical announced today the issuance of two new patents by the USPTO titled "Anchors and locks for percutaneous valve implants" (Patent No. 11,058,411) and "Percutaneous Valve repair and replacement" (Patent No. 11,058,537).

VALFIX Medical Ltd. is pleased to announce the approval from both the European Patent Office (EPO) and the Israeli Patent Office (IPO) for its patent, titled "Percutaneous valve repair and replacement".

The European Commission recently awarded VALFIX Medical with the Seal of Excellence, a high-quality certificate for first-class innovative ideas worthy of investment.

VALFIX Medical Ltd. is pleased to announce the issuance of US Patent No. 10,463,486 issued November 5th, 2019. This is the second US patent granted for VALFIX and was approved only 2 years and 9 months since its priority date.

VALFIX Medical Inc. announces today an investment from California based angel group, Life Science Angels (LSA). This investment is part of the company's third investment round and concludes a meticulous due diligence process led by Dr.